Lilly's AWARD-PEDS trial investigating use of Trulicity® (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo | Eli Lilly and Company - Eli Lilly

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

AWARD-PEDS results presented at ADA's 82nd Scientific Sessions® and simultaneously published in the New England Journal of Medicine demonstrate A1C reductions of up to 1.5% for Trulicity compared… [+15731 chars]

full article...